Home › Langerhans-Cell Histiocytosis › Ohio
Langerhans-Cell Histiocytosis clinical trials in Ohio
3 studies for Langerhans-Cell Histiocytosis are looking for participants at sites in Ohio.
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
- Rainbow Babies and Childrens Hospital, Cleveland
- Nationwide Children's Hospital, Columbus
- Dayton Children's Hospital, Dayton
RecruitingPhase 2
180 Days – 22 Years · All sexes · Updated Oct 2, 2026 · NCT05828069Mirdametinib in Histiocytic Disorders
- Cincinnati Children's Hospital Medical Center, Cincinnati
RecruitingPhase 2
Ages 2 and older · All sexes · Updated Sep 21, 2026 · NCT06153173Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- Nationwide Children's Hospital, Columbus
RecruitingPhase 3
Up to age 21 · All sexes · Updated Sep 11, 2025 · NCT02670707From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.